
    
      In Part One, 8 subjects with moderate hepatic impairment (Child Pugh Scale B) and 8 matched
      healthy subjects will be enrolled. In Part 2, 8 subjects with mild hepatic impairment
      (Child-Pugh Scale A) and 8 matched healthy subjects will be enrolled. In Part 3, 3 subjects
      with severe hepatic impairment (Child-Pugh Scale C) will be enrolled. Parts 2 and 3 will only
      be initiated if the criteria per protocol is met in Part One. The pharmacokinetics and safety
      profiles will be compared between hepatic impaired subjects and healthy subjects.
    
  